ArticleScientific reports2026
Vascularized human brain organoids as a model of the brain-peripheral axis in HIV-1 neuropathogenesis.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Structure-Property-Function Relationships in Stimuli-Responsive Hydrogels for Brain Organoid Vascularization.Gels (Basel, Switzerland) · 2026Review
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Advances in stem cell biology and tissue engineering have enabled the generation of brain organoids from human induced pluripotent stem cells (hiPSCs), providing powerful platforms to model human brain development and neurodegenerative diseases. However, the lack of vascularization in conventional brain organoids limits nutrient and oxygen diffusion, thereby constraining their viability and physiological relevance. To overcome this limitation, we developed vascularized brain organoids using both normal hiPSCs and hiPSCs overexpressing the endothelial transcription factor ETS variant 2 (ETV2). Furthermore, this model also provides a unique opportunity to investigate how HIV-1 disrupts endothelial integrity within the CNS. Organoids were generated through co-culture differentiation using a modified protocol optimized to promote vascularization. Following characterization, organoids were exposed to HIV-1-infected PMPs in the presence or absence of ART. Viral replication was quantified using p24 ELISA and qRT-PCR assays. Our findings demonstrate the successful development of vascularized brain organoids (EndohBOs), which exhibit robust expression of CD31, Collagen IV, and GFAP footing, recapitulating key structural and cellular components of the human neurovascular unit. Notably, EndohBOs supported a higher number of transmigrated HIV-1-infected Primitive macrophage progenitor cells or Monocytes (PMPs) as evidenced by imaging. Interestingly, Antiretroviral therapy (ART) treatment failed to substantially reduce viral RNA or p24 levels, suggesting that despite ART exposure, viral replication persisted within EndohBOs. Overall, this vascularized brain organoid model provides a physiologically relevant human system to study the effects of HIV-1 and other neurotropic pathogens on the CNS. It also offers a promising platform for testing CNS-targeted therapeutic interventions aimed at restoring neurovascular integrity and mitigating HIV-induced barrier disruption.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.